Skip to content

Category: Press Releases

Statement on the VALID Act of 2022

Friends of Cancer Research (Friends) applauds the thoughtful work in constructing the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2022 – and particularly for including it in the Senate HELP user fee reauthorization bill (The FDA Safety and Landmark Advancements (FDASLA) Act). Diagnostic tests continue to be a growing component of cancer research and patient…

New Research Shows Breakthrough Therapy Designated Drugs Provide Maximum Benefit to Patients

A new analysis conducted by Friends of Cancer Research (Friends) published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, reveals that U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) criteria select drugs that lead to better outcomes for patients with lung cancer. The study titled “Breakthrough Therapy…

Friends of Cancer Research Statement on the Proposed House and Senate FDA User Fee Legislation

Friends of Cancer Research (Friends) is encouraged by the notable progress being made within the House and Senate on the upcoming reauthorization of the FDA user fee programs.  Representative Pallone and Representative McMorris-Rogers’s bill in the House as well as Senator Murray and Senators Burr’s newly released legislation in the Senate both support FDA programs to…

Dr. Ned Sharpless Stepping Down as National Cancer Institute Director

Friends of Cancer Research (Friends) would like to thank Dr. Ned Sharpless for his tireless public service and scientific leadership as Director of the National Cancer Institute (NCI) as well as his tenure as acting Commissioner of the U.S. Food and Drug Administration (FDA). “Dr. Sharpless deserves our country’s deep gratitude for his years of…

Friends of Cancer Research Statement Thanking Dr. Janet Woodcock for Service as Acting FDA Commissioner

Friends of Cancer Research (Friends) would like to thank Dr. Janet Woodcock for serving as Acting Commissioner of the Food and Drug Administration (FDA) and is looking forward to working with Dr. Woodcock as Principal Deputy Commissioner of the Agency. The FDA has significant work in the months ahead to navigate ongoing actions related to…

Statement from Friends of Cancer Research on Dr. Robert Califf’s Confirmation as FDA Commissioner

Friends of Cancer Research (Friends) would like to congratulate Dr. Robert Califf on his bipartisan confirmation today as FDA Commissioner. The United States is at a pivotal moment for public health, and the leadership Dr. Califf will bring to the FDA will be paramount to assuring the safety, effectiveness, and security of human drugs, and…

Statement from Friends of Cancer Research on President & Dr. Biden’s Cancer Moonshot

Friends of Cancer Research (Friends) would like to congratulate President Biden and Dr. Biden on the announcement of a new Cancer Moonshot. We applaud the ambitious new goals and objectives that will be instrumental in changing the trajectory of cancer care and treatment and ending cancer as we know it today. We strongly support the…

New HRD Publication Sets the Stage for Unique Collaboration

Friends of Cancer Research (Friends) is excited to announce its latest publication “Homologous Recombination Deficiency: Concepts, Definitions, and Assays.” Findings from this manuscript set the foundation for the ongoing Homologous Recombination Deficiency (HRD) Harmonization Project, a unique research partnership focused on developing strategies to assess assay performance and align on methods for measuring and using…

Friends of Cancer Research Announces Results from Phase 2 of Tumor Mutational Burden Harmonization Project

Washington, DC – Friends of Cancer Research (Friends) is pleased to announce findings from the final analysis of our TMB Harmonization Project published this week in Annals of Oncology, “Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.”  Tumor mutational burden, or TMB, is…

Individuals with Cancer Must Be Included in COVID-19 Vaccine Trials

New ASCO-Friends Joint Position Statement Encourages Enrollment of Patients with Cancer in Vaccine Studies Alexandria, Va. and Washington, DC. – Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research…